| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-864 | |
| Phytochemical name or plant extracts | Strophanthidin | |
| PMID | 32010609 | |
| Literature evidence | Taken together, this study demonstrates the viability of strophanthidin as a promising anticancer agent, which may serve as a new anticancer drug. | |
| IUPAC name | (3S,5S,8R,9S,10S,13R,14S,17R)-3,5,14-trihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde | |
| Phytochemicals’ class or type of plant extracts | Cardiac glycoside | |
| Source of phytochemicals or plant Extracts | Strophanthus kombe | |
| Geographical availability | Botswana, Caprivi Strip, Kenya, Malawi, Mozambique, Northern Provinces, Tanzania, Zambia, Zimbabwe | |
| Plant parts | NA | |
| Other cancers | Breast cancer, Liver cancer | |
| Target gene or protein | MEK1, PI3K, AKT, mTOR, Gsk3α, β-catenin | |
| Gene or Protein evidence | Moreover, strophanthidin inhibited the expression of several key proteins such as MEK1, PI3K, AKT, mTOR, Gsk3α, and β-catenin from MAPK, PI3K/AKT/mTOR, and Wnt/β-catenin signaling. | |
| Target pathways | MAPK, PI3K/AKT/mTOR, and Wnt/β-catenin signaling | |
| IC50 | 1.12 ± 0.04 μM against MCF-7 | |
| Potency | Taken together, this study demonstrates the viability of strophanthidin as a promising anticancer agent, which may serve as a new anticancer drug. | |
| Cell line/ mice model | MCF-7, A549, and HepG2 | |
| Additional information | When the calcium influx is already increased by high calcium or norepinephrine, strophanthidin has its usual inotropic effect even in the presence of TTX. In conclusion, the positive inotropic effect of strophanthidin requires that an increase in aiNa be associated with suitable calcium availability. | |
| PubChem ID | 6185 | |
| Additional PMIDs | 6325584 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:81909-1 | |
| Safety | NA |